Zynerba Pharmaceuticals Inc. (NASDAQ: ZYNE) is 3.64% higher on its value in year-to-date trading and has touched a low of $2.55 and a high of $15.70 in the current 52-week trading range. The ZYNE stock was last observed hovering at around $6.26 in the last trading session, with the day’s gains setting it 0.07% off its average median price target of $18.00 for the next 12 months. It is also 75.65% off the consensus price target high of $26.00 offered by 7 analysts, but current levels are -40.67% lower than the price target low of $4.50 for the same period.
Gold bugs are shouting from the rooftops in excitement, but that doesn’t mean you rush out and just buy any gold stock…That’s why we laid out The 2021 Ultimate Gold Portfolio – to dissect the treasure from the trash.
Currently trading at $6.33, the stock is 13.70% and 30.57% above its SMA20 and SMA50 respectively. However, with a daily trading volume of 1.19 million and changing 1.12% at the moment leaves the stock 10.60% off its SMA200. ZYNE registered -50.12% loss for a year compared to 6-month gain of 3.30%. The firm has a 50-day simple moving average (SMA 50) of $5.23 and a 200-day simple moving average (SMA200) of $4.81.
The stock witnessed a 1.13% loss in the last 1 month and extending the period to 3 months gives it a 63.45%, and is 14.03% up over the last 5 days. If we measure the stock’s price variations over the week and the month, we find that the volatility rates stand at 12.29% over the week and 9.14% over the month.
Distance from 52-week low is 148.24% and -59.67% from its 52-week high.
Zynerba Pharmaceuticals Inc. (ZYNE) Analyst Forecasts
Analyst recommendations provided by FactSet shows that the consensus forecast for Zynerba Pharmaceuticals Inc. (ZYNE) is a “Buy”. 7 analysts offering their recommendations for the stock have an average rating of 1.90, where 1 rate it as a Hold and 0 think it is a “Overweight”. 6 of the analysts rate the stock as a “Buy”. 0 analysts have rated the stock as a Sell or Underperform.
Zynerba Pharmaceuticals Inc. is expected to release its quarterly report on 08/05/2020 and quarterly earnings per share for the current quarter are estimated at -$0.45.The EPS is expected to grow by 42.60% this year.
Zynerba Pharmaceuticals Inc. (ZYNE) Top Institutional Holders
113 institutions hold shares in Zynerba Pharmaceuticals Inc. (ZYNE), with 3.07M shares held by insiders accounting for 12.32% while institutional investors hold 53.54% of the company’s shares. The shares outstanding are 23.40M, and float is at 22.06M with Short Float at 27.27%. Institutions hold 46.94% of the Float.
The top institutional shareholder in the company is Vanguard Group, Inc. (The) with over 1.61 million shares valued at $6.16 million. The investor’s holdings represent 6.45% of the ZYNE Shares outstanding. As of Mar 30, 2020, the second largest holder is Blackrock Inc. with 1.51 million shares valued at $5.78 million to account for 6.05% of the shares outstanding. The other top investors are ETF Managers Group, LLC which holds 1.21 million shares representing 4.84% and valued at over $4.63 million, while Portolan Capital Management, LLC holds 1.74% of the shares totaling 0.43 million with a market value of $1.67 million.
Zynerba Pharmaceuticals Inc. (ZYNE) Insider Activity
A total of 0 insider transactions have happened at Zynerba Pharmaceuticals Inc. (ZYNE) in the last six months, with sales accounting for 0 and purchases happening 0 times.
Zynerba Pharmaceuticals Inc. (ZYNE): Who are the competitors?
Omeros Corporation (OMER) is -3.73% down on the 1-year trading charts. Short interest in the company’s stock has risen 15.17% from the last report on May 14, 2020 to stand at a total of 5.76 million short shares sold with a short interest ratio of 4.5.